Ceftazidime: β-Lactamase-Resistant Cephalosporin for Gram-Negative Infection Research

Executive Summary: Ceftazidime (SKU B3539) is a third-generation cephalosporin antibiotic with broad spectrum activity, notably against Pseudomonas aeruginosa and β-lactamase-producing Gram-negative bacteria, and is distributed by APExBIO (APExBIO product page). It is uniquely resistant to hydrolysis by most β-lactamases, making it a cornerstone for both clinical and experimental applications involving multidrug-resistant Enterobacteriaceae. Its mechanism involves inhibition of bacterial cell wall synthesis, leading to bactericidal effects. Ceftazidime demonstrates lower efficacy against Staphylococcus aureus than earlier-generation cephalosporins, which is critical for appropriate spectrum selection. Recent surveillance confirms its role as the most active cephalosporin against P. aeruginosa and a preferred agent for respiratory Gram-negative infections (Chen et al., 2025).

Biological Rationale

Ceftazidime is classified as a third-generation cephalosporin. It is specifically engineered for activity against Gram-negative aerobes, including Pseudomonas species (Chen et al., 2025). Its chemical structure (C₂₂H₂₂N₆O₇S₂, MW 546.58) confers resistance to most common β-lactamases. This property is essential for combating infections caused by β-lactamase-producing Enterobacteriaceae, which have increased in prevalence in both clinical and research settings. The compound is highly soluble in DMSO (≥21.25 mg/mL), but insoluble in water and ethanol, which affects protocol design and solution preparation (APExBIO). Ceftazidime is recommended for storage at -20°C to maintain its chemical and microbiological stability. The typical clinical and experimental dosage ranges from 3–6 g/day, administered in divided doses.

Mechanism of Action of Ceftazidime

Ceftazidime exerts its antibacterial effect by binding to penicillin-binding proteins (PBPs), particularly those involved in the final stages of bacterial cell wall peptidoglycan synthesis. This results in inhibition of cell wall cross-linking and leads to rapid bacterial lysis and cell death (Related article). Its resistance to most β-lactamases is due to the unique configuration of its β-lactam ring. This makes it an effective choice against organisms that have acquired resistance to other β-lactam antibiotics, such as ampicillin or first-generation cephalosporins. Notably, ceftazidime does not inhibit cell wall synthesis in Gram-positive cocci as effectively as earlier generations, which must be considered in spectrum selection.

Evidence & Benchmarks

• Ceftazidime demonstrates superior in vitro activity against P. aeruginosa compared to other cephalosporins (Chen et al. 2025, BMC Microbiology).
• Among carbapenem-resistant Enterobacter cloacae isolates, ceftazidime/avibactam resistance rates are significantly higher in strains positive for carbapenemase-encoding genes (CEGs) (Chen et al. 2025, BMC Microbiology).
• Ceftazidime remains effective against β-lactamase-producing Enterobacteriaceae except when co-resistance is mediated by acquired carbapenemases (Chen et al. 2025, BMC Microbiology).
• Stock solutions of ceftazidime retain >95% activity for at least 7 days at -20°C (APExBIO datasheet, product page).
• Clinical and laboratory protocols recommend ceftazidime at 3–6 g/day (divided 2–4x) for pneumonia and bronchitis caused by susceptible Gram-negative bacteria (Supporting article).
• In infection models, ceftazidime improves reproducibility and reduces experimental confounders in Gram-negative viability assays (Optimizing Gram-Negative Research).

Applications, Limits & Misconceptions

Ceftazidime (see product page) is widely used in both clinical and research environments to treat and model infections caused by Gram-negative bacteria, especially when β-lactamase-mediated resistance is present. It is the first-line cephalosporin for P. aeruginosa and is routinely used in cell-based infection models where β-lactamase resistance is a confounder. Its insolubility in water and ethanol restricts its use in aqueous-only protocols. Ceftazidime is less effective against Gram-positive cocci and should not be used when Staphylococcus aureus is the primary target. Resistance may develop rapidly if used as monotherapy against organisms with mobile carbapenemase genes, such as bla_NDM-1 or bla_KPC-2 (Chen et al. 2025, BMC Microbiology).

Common Pitfalls or Misconceptions

• Ceftazidime is not universally effective against all β-lactamase-producing organisms; carbapenemase or extended-spectrum β-lactamase (ESBL) producers may be resistant.
• It is not recommended for primary therapy of Gram-positive infections due to lower intrinsic activity.
• Stock solutions must be stored at -20°C; higher temperatures rapidly degrade potency.
• Water or ethanol cannot be used as solvents for ceftazidime powder; DMSO is required for solubility.
• Monotherapy with ceftazidime in high-prevalence carbapenemase settings risks rapid emergence of resistance.

Workflow Integration & Parameters

For research applications, ceftazidime is most effectively used in cell viability, bacterial infection, and antimicrobial resistance assays targeting Gram-negative bacteria. Prepare stock solutions at ≥21.25 mg/mL in DMSO and store aliquots at -20°C, discarding unused portions after 7 days to maintain reproducibility (APExBIO). In clinical or translational models, dose responses between 3–6 g/day (divided) are standard. For detailed protocols and scenario-driven guidance, see Optimizing Gram-Negative Research (which focuses on cell-based assay design, while this article provides more recent resistance data and benchmark best practices) and Data-Backed Solutions (which details troubleshooting for antimicrobial resistance assays; this article updates the context with new post-pandemic surveillance results). For a genomic-era strategy context, consult Ceftazidime in the Genomic Era, which this article extends by providing practical workflow parameters and resistance gene prevalence data.

Conclusion & Outlook

Ceftazidime remains a core reagent for Gram-negative infection research and clinical management, particularly where β-lactamase resistance is prevalent. Its stability, spectrum, and mechanism of action position it as an indispensable tool for experiments targeting Pseudomonas aeruginosa and Enterobacteriaceae. However, the rise of carbapenemase-encoding genes like bla_NDM-1 demands ongoing surveillance and informed protocol design. APExBIO's Ceftazidime (SKU B3539) provides researchers with a validated, high-purity reagent that meets current experimental and translational needs. Future research should focus on combination therapies and next-generation cephalosporins to address evolving resistance dynamics (Chen et al., 2025).